PFI ANDA
This article was originally published in The Tan Sheet
Executive Summary
Pharmaceutical Formulations, Inc.'s ibuprofen/pseudoephedrine hydrochloride tablets (Whitehall-Robins' Advil Cold & Sinus) approved by FDA April 8. ANDA 75-588 marks second private label approval referencing the analgesic. Ranbaxy Pharmaceuticals subsidiary Ohm Labs, which licensed its product to Perrigo, received 180-day, first-to-file exclusivity (1"The Tan Sheet" May 7, 2001, p. 8)...
You may also be interested in...
Perrigo New Product Launches, PPA Replacements Slated For August
Perrigo expects to offer famotidine Acid Reducer, a generic version of J&J/Merck's Pepcid AC, no later than June, the private labeler told analysts during a conference call May 1.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.